
    
      100 patients with verified EDS-IV syndrome are included. Patients are randomized to either
      celiprolol (50 to 400 mg BID)or no treatment. Patients who are not randomized enter a
      longitudinal survey of events. The hypothesis is a 50% reduction in the occurrence of
      cardiovascular events under treatment, assessed by a blinded, independent events committee.
    
  